accounted for 15 (0·5%) of the total of 2860 deaths in women of any ER status in the 2013 report (seven deaths in 36 patients randomly assigned to 10 years vs eight deaths in 36 patients randomised to 5 years, including three deaths vs no deaths without prior recurrence).
Exclusion of that centre's followup data from the 2013 Lancet report 1 necessarily has exactly no effect on the findings in ER-positive or ER-negative disease, and in ER-unknown disease it leaves the all-cause mortality rate ratio (RR) and its 95% CI unchanged to two decimal places. However, it increases or decreases by 0·01 of some RRs for particular categories of death in women with ER-unknown disease (or in all women, irrespective of whether their ER status was known). The 2013 report and online material are appended to this letter as an appendix, with tracked changes showing the slight effects of excluding this centre's follow-up.
The Lancet 2013 paper was, as its title states, concerned with the findings for ER-positive disease, as this is the main thing nowadays that is clinically relevant. Its analyses of results in ER-positive disease and in ER-negative disease are unchanged by the exclusion of all follow-up data from this one centre, because all women from this centre had unknown ER status. Additionally, the number of deaths excluded was relatively small and happened to be balanced between the two trial treatment groups, so their removal had no material effect on any of the trial findings in the text or appendix. Hence, exclusion from the 2013 Lancet report of the follow-up from this one centre has no implications for patient care.
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Christina.Davies@ndph.ox.ac.uk ATLAS International Co-ordinating Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK 10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS ATLAS is an international trial of the main effects of prolonging adjuvant tamoxifen. It involves 15 000 women with early breast cancer, randomised in 1995-2005 at 402 centres in many countries. Its 2013 findings 1 showed that in oestrogen receptor (ER)-positive disease, 5 years of tamoxifen is significantly less effective than 10 years in reducing 15-year breast cancer mortality, and its 20-year findings are to be reported in 2018.
Most participants were diagnosed in the 1990s, when ER testing was unavailable in some centres, so a minority had disease of unknown ER status. Findings for ER-unknown disease are not as directly relevant to practice as findings for ER-positive disease, so the 2013 report published in The Lancet 1 mainly focused on the findings in ER-positive disease. The authors noted, however, that the apparent effects in ER-unknown disease (given in an online appendix) were intermediate between no material effect, as in ER-negative disease, and the benefit reported in ER-positive disease.
Recently, central checks revealed that at one centre several annual follow-up forms were discrepant with national mortality records. This finding triggered a site visit that confirmed the discrepancies, so the ATLAS data monitoring committee decided (blind to any effects on trial findings) to exclude all follow-up from that centre. The UK principal investigators and steering committee chairs concurred, as did OXTREC, the international ethics committee responsible for approving ATLAS annually, and the relevant national authorities have been informed. All 72 patients from that one centre had unknown ER status and had been randomly assigned to 10 years versus 5 years of tamoxifen, and they Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet 2016; 388: 3027-35-In the first sentence of the Results in the Article, the number of children who did not live to age 5 years should have been 5·942 million. Data in table 2 have been updated. These corrections have been made to the online version as of May 11, 2017.
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April 27, 2017 http://dx.doi.org/10.1016/ S0140-6736(17)31004-8 Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-16-Following a routine internal audit, the findings in this Article have been slightly updated. In the main paper, this has affected only the incidence of ischaemic heart disease (Summary Findings; last paragraph of Results; table 2), mortality from causes other than breast cancer (Summary Findings), and, also in table 2, mortality among women with unknown ER status (and hence among women with any ER status). No event rate ratio has been changed by more than 0·01. The main paper and appendix have been updated online as of April 27, 2017.
The AVERT Trial Collaboration group. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet 2015; 386: 46-55-This Open Access Article should have been distributed under the terms of CC BY. This correction has been made to the online version as of May 11, 2017.
